Results 191 to 200 of about 8,578 (238)

Naptumomab estafenatox: a new immunoconjugate

Expert Opinion on Biological Therapy, 2010
New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.This review examines the preclinical and the published clinical data with regards to naptumomab.This review provides the reader with an ...
Matthew K, Robinson, R Katherine, Alpaugh, Hossein, Borghaei   +2 more
openaire   +2 more sources

Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments.

Critical reviews in oncology/hematology
Immunoconjugates are promising molecules combining antibodies with different agents, such as toxins, drugs, radionuclides, or cytokines that primarily aim to target tumor cells.
Amir Saamaan Fattahi, M. Jafari, Ghazal Farahavar, S. Abolmaali, A. Tamaddon   +4 more
semanticscholar   +1 more source

THE POTENTIAL FOR IMMUNOCONJUGATES IN LYMPHOMA THERAPY

Hematology/Oncology Clinics of North America, 1997
Contemporary combination chemotherapy offers curative treatment for 30% to 50% of patients with advanced-stage, aggressive non-Hodgkin's lymphomas (NHL). However, conventional therapies cure few patients with indolent lymphomas or relapsed lymphomas of any histology.
S Y, Liu, O W, Press
openaire   +2 more sources

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates

Nuclear Medicine Communications, 1995
This paper describes in vitro cytotoxicity experiments with 213Bi- and 225Ac-immunoconjugates on the human epidermoid tumour cell line A431 using a blood group A-reactive murine IgG (2D11) as the specific antibody and MOPC 21 as the control antibody. With both radionuclides, specific cell-killing was achieved. The observed cytotoxicity of 213Bi (T1/2 -
F M, Kaspersen, E, Bos, A V, Doornmalen, M W, Geerlings, C, Apostolidis, R, Molinet   +5 more
openaire   +2 more sources

Stabilisation of immunoconjugates by trehalose

Biotechnology Letters, 2000
Stable immunoconjugates were prepared in the presence of 400 mM trehalose. Their residual activity after freeze-drying, rehydration and incubation for 9 h at 40 °C was 35%. Freeze-dried conjugates containing 400 mM trehalose incubated at 40 °C for 4 days retained 80% of their original activity.
Maria Izabel Esteves, Wagner Quintilio, Rony A. Sato, Isaías Raw, Pedro Soares de Araujo, Maria Helena Bueno da Costa   +5 more
openaire   +1 more source

Immunoconjugates and Immunotoxins for Therapy of Carcinomas

1995
Publisher Summary This chapter reviews preclinical findings that predict that there is a role for monoclonal antibody (MAb)-based drug conjugates and immunotoxins for the targeted therapy of carcinomas. The use of immunoconjugates consisting of clinically known anticancer drugs offers several advantages.
I, Hellström, K E, Hellström, C B, Siegall, P A, Trail   +3 more
openaire   +2 more sources

Potential Use of Immunoconjugates for AIDS Therapy

AIDS Research and Human Retroviruses, 1992
More than a dozen of hybrid proteins possessing reactivity with human immunodeficiency virus-type l-(HIV-l) infected cells and cytotoxicity have been produced and studied by several groups. These proteins are prepared either by chemical cross-linking of a toxin and a carrier molecule or by expressing fused genes of the two moieties.
Y W, Kim, T W, Chang
openaire   +2 more sources

Intraperitoneal immunoconjugates.

Cancer research, 1990
Intracavitary instillation of radioantibodies has been proposed as therapy for anatomically confined malignant disease. To evaluate this therapeutic strategy, a monoclonal antibody reactive with human transferrin receptor (7D3) was evaluated for localization in a human malignant mesothelioma transplanted i.p. in athymic nude mice.
T W, Griffin, J, Collins, F, Bokhari, M, Stochl, A B, Brill, T, Ito, G, Emond, H, Sands   +7 more
openaire   +1 more source

Radioimmunotherapy with Alpha-Particle-Emitting Immunoconjugates

Science, 1988
Alpha particles are energetic short-range ions whose higher linear energy transfer produces extreme cytotoxicity. An α-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared.
R M, Macklis, B M, Kinsey, A I, Kassis, J L, Ferrara, R W, Atcher, J J, Hines, C N, Coleman, S J, Adelstein, S J, Burakoff   +8 more
openaire   +2 more sources

Immunoconjugate Anticancer Therapeutics

2009
Immunoconjugate therapy has entered the mainstream of cancer management with the regulatory approval and the bench to bedside transition of three antibody conjugates for lymphoma and leukemia. A number of antibody conjugates of radionuclides, drugs, and protein toxins are in various stages of clinical development.
Serengulam V. Govindan, David M. Goldenberg   +1 more
openaire   +1 more source